EPB41L3 antisense RNA 1 (EPB41L3-AS1)

EPB41L3 antisense RNA 1 (EPB41L3-AS1) is a long non-coding RNA (lncRNA) that is transcribed antisense to the EPB41L3 (erythrocyte membrane protein band 4.1 like 3) gene. Like other antisense RNAs, it is thought to be involved in the regulation of its sense gene (EPB41L3) expression, possibly affecting mRNA stability, splicing, or translation of the sense transcript. However, little is reported about the molecular function, biological activities, or disease relevance of EPB41L3-AS1 specifically. Most available scientific literature and cancer studies focus on the protein-coding EPB41L3 gene (a cytoskeleton-associated, FERM domain protein with tumor suppressor properties in several cancers) rather than the antisense lncRNA[1][2][3]. There is no evidence that EPB41L3-AS1 is a validated therapeutic target, approved biomarker, or that any drugs directly interact with it. Important note: Your original query refers to "EPB41L3 antisense RNA 1" (EPB41L3-AS1) and not the protein-coding gene "EPB41L3" (which is a well-studied tumor suppressor and cytoskeletal protein). Almost all of the provided literature and database results address EPB41L3 protein and its role in cancer, but not the lncRNA EPB41L3-AS1. Therefore, EPB41L3-AS1 is not considered a therapeutic target, and there is essentially no data about its druggability, established function, or disease relevance. Most research, clinical studies, or drug interactions attributed to "EPB41L3" refer to the protein, not the lncRNA, so treating EPB41L3-AS1 as a drug target or receptor would be incorrect given current knowledge[1][2][3].

Other names

EPB41L3-AS1EPB41L3 antisense RNA 1

Not established (No drugs known or approved that directly target EPB41L3-AS1)